{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:54:45Z","timestamp":1791089685742,"version":"4.1.0"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["336449"],"award-info":[{"award-number":["336449"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["351568"],"award-info":[{"award-number":["351568"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["336449"],"award-info":[{"award-number":["336449"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["351568"],"award-info":[{"award-number":["351568"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA21110"],"award-info":[{"award-number":["CA21110"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA21110"],"award-info":[{"award-number":["CA21110"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101095635"],"award-info":[{"award-number":["101095635"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101137315"],"award-info":[{"award-number":["101137315"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101095635"],"award-info":[{"award-number":["101095635"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101095635"],"award-info":[{"award-number":["101095635"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101095084"],"award-info":[{"award-number":["101095084"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101191729"],"award-info":[{"award-number":["101191729"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004504","name":"Lietuvos Mokslo Taryba","doi-asserted-by":"publisher","award":["S-EURONANOMED-22-1"],"award-info":[{"award-number":["S-EURONANOMED-22-1"]}],"id":[{"id":"10.13039\/501100004504","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoarthritis (OA) remains a major cause of disability worldwide; however, current non-surgical treatments offer transient symptom relief without altering disease course. This leaves a therapeutic gap for patients with early-to-moderate disease who are not candidates for surgery but continue to experience pain and functional limitation. Intra-articular interventions such as non-steroidal anti-inflammatory drugs, hyaluronic acid, and platelet-rich plasma may ease symptoms, but do not modify disease progression. By contrast, cell therapy products hold promise as regenerative approaches that may both alleviate pain and influence disease trajectory. Cell therapy products for knee OA exert multimodal effects through paracrine and immunomodulatory mechanisms, including modulation of synovial inflammation, attenuation of senescence-associated pathways, and support of extracellular matrix production. Despite encouraging preclinical and clinical signals, only a few cell therapy products have been approved globally, and most remain in development. However, substantial translational challenges remain, including variability in cell source and potency, limited persistence in joint environment, small clinical trial sizes, and regulatory and manufacturing hurdles. To achieve broader adoption, it will be essential to demonstrate superiority to minimally manipulated orthobiologics, clarify redosing strategies, and generate robust long-term evidence. This Review discusses recent clinical trial data, mechanistic insights, regulatory considerations, and operational challenges shaping the evolving role of cell therapy products for OA as next-generation candidates to bridge the gap between pharmacological and surgical interventions. In addition, this Review is written to support regulatory agencies as well as academics and clinicians involved in the development and evaluation of cell therapy products.<\/jats:p>","DOI":"10.1038\/s12276-026-01726-y","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:36:27Z","timestamp":1781076987000},"page":"1754-1771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-generation therapies for osteoarthritis: the evolving role of cell therapy products"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-0269","authenticated-orcid":false,"given":"Valtteri","family":"Peitso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3067-7073","authenticated-orcid":false,"given":"Ron","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3080-9640","authenticated-orcid":false,"given":"Karman","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-0346","authenticated-orcid":false,"given":"Simone","family":"Ponta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-9779","authenticated-orcid":false,"given":"Rana","family":"Smaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-3559","authenticated-orcid":false,"given":"Nadia","family":"Benkirane-Jessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-9307","authenticated-orcid":false,"given":"Nancy P.","family":"Duarte-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-4680","authenticated-orcid":false,"given":"Tobias","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-9208","authenticated-orcid":false,"given":"Goncalo","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-752X","authenticated-orcid":false,"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-1286","authenticated-orcid":false,"given":"Ali","family":"Mobasheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"1726_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00163-7","author":"JD Steinmetz","year":"2023","unstructured":"Steinmetz, J. D. et al. Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(23)00163-7 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1726_CR2","doi-asserted-by":"publisher","unstructured":"Tang, T. et al. Global burden of osteoarthritis in middle-aged adults (40\u201359 years): estimates from the global burden of disease 2021 study. Rheumatology https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAF475 (2025).","DOI":"10.1093\/RHEUMATOLOGY\/KEAF475"},{"key":"1726_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/BJSPORTS-2020-103671","author":"TGH Wiggers","year":"2021","unstructured":"Wiggers, T. G. H., Winters, M., Van Den Boom, N. A. C., Haisma, H. J. & Moen, M. H. Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials. Br. J. Sports Med. https:\/\/doi.org\/10.1136\/BJSPORTS-2020-103671 (2021).","journal-title":"Br. J. Sports Med."},{"key":"1726_CR4","doi-asserted-by":"publisher","unstructured":"Arden, N. K. et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. https:\/\/doi.org\/10.1038\/s41584-020-00523-9 (2020).","DOI":"10.1038\/s41584-020-00523-9"},{"key":"1726_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.159","author":"CH Evans","year":"2013","unstructured":"Evans, C. H., Kraus, V. B. & Setton, L. A. Progress in intra-articular therapy. Nat. Rev. Rheumatol. https:\/\/doi.org\/10.1038\/nrrheum.2013.159 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1726_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/KSA.70001","author":"L de Girolamo","year":"2025","unstructured":"de Girolamo, L. et al. The use of injectable orthobiologics for knee osteoarthritis: a formal ESSKA-ORBIT consensus. Part 2 \u2014 cell-based therapy. Knee Surg. Sports Traumatol. Arthrosc. https:\/\/doi.org\/10.1002\/KSA.70001 (2025).","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"key":"1726_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.SEMARTHRIT.2019.04.008","author":"O Bruy\u00e8re","year":"2019","unstructured":"Bruy\u00e8re, O. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin. Arthritis Rheum. https:\/\/doi.org\/10.1016\/J.SEMARTHRIT.2019.04.008 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"1726_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01305-x","author":"NR Fuggle","year":"2025","unstructured":"Fuggle, N. R. et al. Novel approaches to the stratified management of knee osteoarthritis. Nat. Rev. Rheumatol. https:\/\/doi.org\/10.1038\/s41584-025-01305-x (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1726_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/S41584-024-01126-4","author":"A Mobasheri","year":"2024","unstructured":"Mobasheri, A. & Loeser, R. Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development. Nat. Rev. Rheumatol. https:\/\/doi.org\/10.1038\/S41584-024-01126-4 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1726_CR10","unstructured":"Considerations in developing a regulatory framework for human cells and tissues and for advanced therapy medicinal products [Internet]. https:\/\/www.who.int\/publications\/m\/item\/considerations-in-developing-a-regulatory-framework-for-human-cells-and-tissues-and-for-advanced-therapy-medicinal-products(2023)."},{"key":"1726_CR11","unstructured":"FDA. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use [Internet]. (2025). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal."},{"key":"1726_CR12","unstructured":"FDA. Regulation of human cells, tissues, and cellular and tissue-based products (HCT\/Ps) \u2014 Small Entity Compliance Guide [Internet]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/regulation-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-small-entity-compliance (2025)."},{"key":"1726_CR13","unstructured":"European Medicines Agency (EMA). Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials \u2014 Scientific guideline [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-scientific-guideline (2025)."},{"key":"1726_CR14","unstructured":"European Medicines Agency (EMA). Clinical investigation of medicinal products used in the treatment of osteoarthritis \u2014 Scientific guideline [Internet]. (2025]. https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-used-treatment-osteoarthritis-scientific-guideline."},{"key":"1726_CR15","unstructured":"European Medicines Agency (EMA). Advanced therapy medicinal products: overview [Internet]. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview (2026)."},{"key":"1726_CR16","unstructured":"Advanced therapy medicinal products: regulation and licensing in UK \u2014 GOV.UK [Internet]. https:\/\/www.gov.uk\/guidance\/advanced-therapy-medicinal-products-regulation-and-licensing (2026)."},{"key":"1726_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/J.SCR.2009.12.003","author":"RC Lai","year":"2010","unstructured":"Lai, R. C. et al. Exosome secreted by MSC reduces myocardial ischemia\/reperfusion injury. Stem Cell Res. https:\/\/doi.org\/10.1016\/J.SCR.2009.12.003 (2010).","journal-title":"Stem Cell Res."},{"key":"1726_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-15376-8","author":"S Cosenza","year":"2017","unstructured":"Cosenza, S., Ruiz, M., Toupet, K., Jorgensen, C. & No\u00ebl, D. Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. Sci. Rep. https:\/\/doi.org\/10.1038\/S41598-017-15376-8 (2017).","journal-title":"Sci. Rep."},{"key":"1726_CR19","doi-asserted-by":"publisher","unstructured":"Mancuso, P., Raman, S., Glynn, A., Barry, F. & Murphy, J. M. Mesenchymal stem cell therapy for osteoarthritis: the critical role of the cell secretome. Front. Bioeng. Biotechnol. https:\/\/doi.org\/10.3389\/FBIOE.2019.00009 (2019).","DOI":"10.3389\/FBIOE.2019.00009"},{"key":"1726_CR20","doi-asserted-by":"publisher","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8 (2016).","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"1726_CR21","doi-asserted-by":"publisher","unstructured":"McInnes, I. B. & Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(17)31472-1 (2017).","DOI":"10.1016\/S0140-6736(17)31472-1"},{"key":"1726_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/J.KNEE.2025.05.027","author":"M Santolini","year":"2025","unstructured":"Santolini, M., Rios, J. L., Custers, R. J. H., Creemers, L. B. & Korpershoek, J. V. Mesenchymal stromal cell injections for osteoarthritis: in vitro mechanisms of action and clinical evidence. Knee https:\/\/doi.org\/10.1016\/J.KNEE.2025.05.027 (2025).","journal-title":"Knee"},{"key":"1726_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/J.JARE.2024.05.004","author":"CM Trigo","year":"2025","unstructured":"Trigo, C. M., Rodrigues, J. S., Cam\u00f5es, S. P., Sol\u00e1, S. & Miranda, J. P. Mesenchymal stem cell secretome for regenerative medicine: where do we stand? J. Adv. Res. https:\/\/doi.org\/10.1016\/J.JARE.2024.05.004 (2025).","journal-title":"J. Adv. Res."},{"key":"1726_CR24","doi-asserted-by":"publisher","unstructured":"Han, Y. et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct. Target. Ther. https:\/\/doi.org\/10.1038\/S41392-022-00932-0 (2022).","DOI":"10.1038\/S41392-022-00932-0"},{"key":"1726_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2025.118317","author":"F Li","year":"2025","unstructured":"Li, F., Venkatesan, J. K., Madry, H. & Cucchiarini, M. Therapeutic strategies targeting synovial cells to treat osteoarthritis. Biomed. Pharmacother. https:\/\/doi.org\/10.1016\/J.BIOPHA.2025.118317 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"1726_CR26","doi-asserted-by":"publisher","DOI":"10.7150\/THNO.20746","author":"LA Vonk","year":"2018","unstructured":"Vonk, L. A. et al. Mesenchymal stromal\/stem cell-derived extracellular vesicles promote human cartilage regeneration in vitro. Theranostics https:\/\/doi.org\/10.7150\/THNO.20746 (2018).","journal-title":"Theranostics"},{"key":"1726_CR27","doi-asserted-by":"publisher","unstructured":"Pi\u00f1eiro-Ramil, M., G\u00f3mez-Seoane, I., Rodr\u00edguez-Cendal, A. I., Fuentes-Boquete, I. & D\u00edaz-Prado, S. Mesenchymal stromal cells-derived extracellular vesicles in cartilage regeneration: potential and limitations. Stem Cell Res. Ther. https:\/\/doi.org\/10.1186\/S13287-025-04135-6 (2025).","DOI":"10.1186\/S13287-025-04135-6"},{"key":"1726_CR28","doi-asserted-by":"publisher","DOI":"10.7150\/THNO.96723","author":"AC Court","year":"2024","unstructured":"Court, A. C. et al. Mitochondrial transfer balances cell redox, energy and metabolic homeostasis in the osteoarthritic chondrocyte preserving cartilage integrity. Theranostics https:\/\/doi.org\/10.7150\/THNO.96723 (2024).","journal-title":"Theranostics"},{"key":"1726_CR29","doi-asserted-by":"publisher","unstructured":"Vega-Letter, A. M. et al. Safety and efficacy of mesenchymal stromal cells mitochondria transplantation as a cell-free therapy for osteoarthritis. J. Transl. Med. https:\/\/doi.org\/10.1186\/S12967-024-05945-7 (2025).","DOI":"10.1186\/S12967-024-05945-7"},{"key":"1726_CR30","doi-asserted-by":"publisher","unstructured":"Pers, Y. M. et al. Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.07.026 (2025).","DOI":"10.1016\/j.ard.2025.07.026"},{"key":"1726_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01020-1","author":"G Copp","year":"2023","unstructured":"Copp, G., Robb, K. P. & Viswanathan, S. Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell. Mol. Immunol. https:\/\/doi.org\/10.1038\/s41423-023-01020-1 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"1726_CR32","unstructured":"Quarterly Gene, Cell, and RNA Therapy Landscape Report | ASGCT \u2014 American Society of Gene & Cell Therapy [Internet]. https:\/\/www.asgct.org\/publications\/landscape-report (2025)."},{"key":"1726_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/CPZ1.596","author":"JL Rios","year":"2022","unstructured":"Rios, J. L. et al. Animal models of osteoarthritis part 1 \u2014 preclinical small animal models: challenges and opportunities for drug development. Curr. Protoc. https:\/\/doi.org\/10.1002\/CPZ1.596 (2022).","journal-title":"Curr. Protoc."},{"key":"1726_CR34","unstructured":"HorStem | European Medicines Agency (EMA) [Internet]. https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/horstem (2025)."},{"key":"1726_CR35","doi-asserted-by":"publisher","DOI":"10.2460\/JAVMA.22.06.0237","author":"E Punz\u00f3n","year":"2022","unstructured":"Punz\u00f3n, E. et al. Equine umbilical cord mesenchymal stem cells demonstrate safety and efficacy in the treatment of canine osteoarthritis: a randomized placebo-controlled trial. J. Am. Vet. Med. Assoc. https:\/\/doi.org\/10.2460\/JAVMA.22.06.0237 (2022).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"1726_CR36","doi-asserted-by":"publisher","unstructured":"Punz\u00f3n, E., Garc\u00eda-Castillo, M., Rico, M. A., Padilla, L. & Pradera, A. Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial. Front. Vet. Sci. https:\/\/doi.org\/10.3389\/FVETS.2023.1098029 (2023).","DOI":"10.3389\/FVETS.2023.1098029"},{"key":"1726_CR37","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/dogstem DogStem | European Medicines Agency (EMA) [Internet] (2025)."},{"key":"1726_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2011.06.008","author":"AI Caplan","year":"2011","unstructured":"Caplan, A. I. & Correa, D. The MSC: an injury drugstore. Cell Stem Cell https:\/\/doi.org\/10.1016\/j.stem.2011.06.008 (2011).","journal-title":"Cell Stem Cell"},{"key":"1726_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/NM.4324","author":"OH Jeon","year":"2017","unstructured":"Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. https:\/\/doi.org\/10.1038\/NM.4324 (2017).","journal-title":"Nat. Med."},{"key":"1726_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/S41584-020-00533-7","author":"PR Coryell","year":"2021","unstructured":"Coryell, P. R., Diekman, B. O. & Loeser, R. F. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat. Rev. Rheumatol. https:\/\/doi.org\/10.1038\/S41584-020-00533-7 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1726_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/JB\/MVAE079","author":"S Yamauchi","year":"2025","unstructured":"Yamauchi, S. & Takahashi, A. Cellular senescence: mechanisms and relevance to cancer and aging. J. Biochem. https:\/\/doi.org\/10.1093\/JB\/MVAE079 (2025).","journal-title":"J. Biochem."},{"key":"1726_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2020.11.007","author":"J Galipeau","year":"2021","unstructured":"Galipeau, J. et al. Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2020.11.007 (2021).","journal-title":"Cytotherapy"},{"key":"1726_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/STCLTM\/SZAC004","author":"Z Weng","year":"2022","unstructured":"Weng, Z. et al. Mesenchymal stem\/stromal cell senescence: hallmarks, mechanisms, and combating strategies. Stem Cells Transl. Med. https:\/\/doi.org\/10.1093\/STCLTM\/SZAC004 (2022).","journal-title":"Stem Cells Transl. Med."},{"key":"1726_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/S13287-025-04360-Z","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Clinical application of mesenchymal stem cells in immunosenescence: a qualitative review of their potential and challenges. Stem Cell Res. Ther. https:\/\/doi.org\/10.1186\/S13287-025-04360-Z (2025).","journal-title":"Stem Cell Res. Ther."},{"key":"1726_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01275-0","author":"C Matta","year":"2025","unstructured":"Matta, C. et al. Insights into chondrocyte populations in cartilaginous tissues at the single-cell level. Nat. Rev. Rheumatol. https:\/\/doi.org\/10.1038\/s41584-025-01275-0 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1726_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/JCP.21258","author":"MB Goldring","year":"2007","unstructured":"Goldring, M. B. & Goldring, S. R. Osteoarthritis. J. Cell Physiol. https:\/\/doi.org\/10.1002\/JCP.21258 (2007).","journal-title":"J. Cell Physiol."},{"key":"1726_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/ART.34453","author":"RF Loeser","year":"2012","unstructured":"Loeser, R. F., Goldring, S. R., Scanzello, C. R. & Goldring, M. B. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum https:\/\/doi.org\/10.1002\/ART.34453 (2012).","journal-title":"Arthritis Rheum"},{"key":"1726_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/NRRHEUM.2010.213","author":"FJ Blanco","year":"2011","unstructured":"Blanco, F. J., Rego, I. & Ruiz-Romero, C. The role of mitochondria in osteoarthritis. Nat. Rev. Rheumatol. https:\/\/doi.org\/10.1038\/NRRHEUM.2010.213 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1726_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.02.036","author":"E Charlier","year":"2019","unstructured":"Charlier, E. et al. Chondrocyte dedifferentiation and osteoarthritis (OA). Biochem. Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2019.02.036 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"1726_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40575-w","author":"E Cavalli","year":"2019","unstructured":"Cavalli, E. et al. Characterization of polydactyly chondrocytes and their use in cartilage engineering. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-019-40575-w (2019).","journal-title":"Sci. Rep."},{"key":"1726_CR51","doi-asserted-by":"publisher","unstructured":"Adkisson, H. D. et al. The potential of human allogeneic juvenile chondrocytes for restoration of articular cartilage. Am. J. Sports Med. https:\/\/doi.org\/10.1177\/0363546510361950 (2010).","DOI":"10.1177\/0363546510361950"},{"key":"1726_CR52","doi-asserted-by":"publisher","unstructured":"Maehara, M. et al. Characterization of polydactyly-derived chondrocyte sheets versus adult chondrocyte sheets for articular cartilage repair. Inflamm. Regen. https:\/\/doi.org\/10.1186\/S41232-017-0053-6 (2017).","DOI":"10.1186\/S41232-017-0053-6"},{"key":"1726_CR53","doi-asserted-by":"publisher","unstructured":"Hamahashi, K. et al. Polydactyly-derived allogeneic chondrocyte cell-sheet transplantation with high tibial osteotomy as regenerative therapy for knee osteoarthritis. npj Regen Med. https:\/\/doi.org\/10.1038\/S41536-022-00272-1 (2022).","DOI":"10.1038\/S41536-022-00272-1"},{"key":"1726_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31658-0","author":"M Mumme","year":"2016","unstructured":"Mumme, M. et al. Nasal chondrocyte-based engineered autologous cartilage tissue for repair of articular cartilage defects: an observational first-in-human trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(16)31658-0 (2016).","journal-title":"Lancet"},{"key":"1726_CR55","doi-asserted-by":"publisher","unstructured":"Seitz, S. et al. Treatment of patellofemoral osteoarthritis with nasal chondrocyte-based engineered cartilage implantation in a randomised, controlled, multicentre phase II clinical trial: protocol for a randomised controlled trial. BMJ Open https:\/\/doi.org\/10.1136\/BMJOPEN-2025-106140 (2025).","DOI":"10.1136\/BMJOPEN-2025-106140"},{"key":"1726_CR56","doi-asserted-by":"publisher","unstructured":"Pelttari, K. et al. Adult human neural crest-derived cells for articular cartilage repair. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3009688 (2014).","DOI":"10.1126\/SCITRANSLMED.3009688"},{"key":"1726_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2023.01.003","author":"A Wixmerten","year":"2023","unstructured":"Wixmerten, A. et al. Good manufacturing practice\u2013compliant change of raw material in the manufacturing process of a clinically used advanced therapy medicinal product \u2014 a comparability study. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2023.01.003 (2023).","journal-title":"Cytotherapy"},{"key":"1726_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2024.11.005","author":"H Tran","year":"2025","unstructured":"Tran, H., Tauro, W., Mobasheri, A. & Noh, M. J. TissueGene-C induces anti-inflammatory activity and M2 macrophage polarization via activation of prostaglandin E2 signaling. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2024.11.005 (2025).","journal-title":"Cytotherapy"},{"key":"1726_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/J.JOCA.2023.07.008","author":"EH Park","year":"2023","unstructured":"Park, E. H. et al. TissueGene-C induces long-term analgesic effects through regulation of pain mediators and neuronal sensitization in a rat monoiodoacetate-induced model of osteoarthritis pain. Osteoarthr. Cartil. https:\/\/doi.org\/10.1016\/J.JOCA.2023.07.008 (2023).","journal-title":"Osteoarthr. Cartil."},{"key":"1726_CR60","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-36-1-59","author":"FL Graham","year":"1977","unstructured":"Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. https:\/\/doi.org\/10.1099\/0022-1317-36-1-59 (1977).","journal-title":"J. Gen. Virol."},{"key":"1726_CR61","doi-asserted-by":"publisher","DOI":"10.1006\/VIRO.1997.8597","author":"N Louis","year":"1997","unstructured":"Louis, N., Evelegh, C. & Graham, F. L. Cloning and sequencing of the cellular\u2013viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology https:\/\/doi.org\/10.1006\/VIRO.1997.8597 (1997).","journal-title":"Virology"},{"key":"1726_CR62","doi-asserted-by":"publisher","unstructured":"Malm, M. et al. Evolution from adherent to suspension: systems biology of HEK293 cell line development. Sci. Rep. https:\/\/doi.org\/10.1038\/S41598-020-76137-8 (2020).","DOI":"10.1038\/S41598-020-76137-8"},{"key":"1726_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/D41586-019-00490-6","author":"AI Caplan","year":"2019","unstructured":"Caplan, A. I. Medicinal signalling cells: they work, so use them. Nature https:\/\/doi.org\/10.1038\/D41586-019-00490-6 (2019).","journal-title":"Nature"},{"key":"1726_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/14653240600855905","author":"M Dominici","year":"2006","unstructured":"Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy https:\/\/doi.org\/10.1080\/14653240600855905 (2006).","journal-title":"Cytotherapy"},{"key":"1726_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2015.11.008","author":"J Galipeau","year":"2016","unstructured":"Galipeau, J. et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2015.11.008 (2016).","journal-title":"Cytotherapy"},{"key":"1726_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.08.002","author":"S Viswanathan","year":"2019","unstructured":"Viswanathan, S. et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy https:\/\/doi.org\/10.1016\/j.jcyt.2019.08.002 (2019).","journal-title":"Cytotherapy"},{"key":"1726_CR67","doi-asserted-by":"publisher","DOI":"10.1242\/DEV.16.3.381","author":"AJ Friedenstein","year":"1966","unstructured":"Friedenstein, A. J., Piatetzky-Shapiro II & Petrakova, K. V. Osteogenesis in transplants of bone marrow cells. Development https:\/\/doi.org\/10.1242\/DEV.16.3.381 (1966).","journal-title":"Development"},{"key":"1726_CR68","doi-asserted-by":"publisher","unstructured":"Barry, F. MSC therapy for osteoarthritis: an unfinished story. J. Orthopaed Res. https:\/\/doi.org\/10.1002\/JOR.24343 (2019).","DOI":"10.1002\/JOR.24343"},{"key":"1726_CR69","doi-asserted-by":"publisher","unstructured":"Murphy, J. M., Fink, D. J., Hunziker, E. B. & Barry, F. P. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. https:\/\/doi.org\/10.1002\/ART.11365 (2003).","DOI":"10.1002\/ART.11365"},{"key":"1726_CR70","doi-asserted-by":"publisher","unstructured":"Pittenger, M. F. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regen Med. https:\/\/doi.org\/10.1038\/s41536-019-0083-6 (2019).","DOI":"10.1038\/s41536-019-0083-6"},{"key":"1726_CR71","doi-asserted-by":"publisher","unstructured":"Toupet, K. et al. Long-term detection of human adipose-derived mesenchymal stem cells after intraarticular injection in SCID mice. Arthritis Rheum https:\/\/doi.org\/10.1002\/ART.37960 (2013).","DOI":"10.1002\/ART.37960"},{"key":"1726_CR72","doi-asserted-by":"publisher","unstructured":"Halvorsen, Y. C., Wilkison, W. O. & Gimble, J. M. Adipose-derived stromal cells \u2014 their utility and potential in bone formation. Int. J. Obes. https:\/\/doi.org\/10.1038\/SJ.IJO.0801503 (2000).","DOI":"10.1038\/SJ.IJO.0801503"},{"key":"1726_CR73","doi-asserted-by":"publisher","unstructured":"Haynesworth, S. E., Goshima, J., Goldberg, V. M. & Caplan, A. I. Characterization of cells with osteogenic potential from human marrow. Bone https:\/\/doi.org\/10.1016\/8756-3282(92)90364-3 (1992).","DOI":"10.1016\/8756-3282(92)90364-3"},{"key":"1726_CR74","doi-asserted-by":"publisher","unstructured":"Miura, M. et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl. Acad. Sci. USA https:\/\/doi.org\/10.1073\/PNAS.0937635100 (2003).","DOI":"10.1073\/PNAS.0937635100"},{"key":"1726_CR75","doi-asserted-by":"publisher","unstructured":"in\u2019t Anker, P. S. et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells https:\/\/doi.org\/10.1634\/STEMCELLS.2004-0058 (2004).","DOI":"10.1634\/STEMCELLS.2004-0058"},{"key":"1726_CR76","doi-asserted-by":"publisher","unstructured":"K\u00f6gler, G. et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med. https:\/\/doi.org\/10.1084\/JEM.20040440 (2004).","DOI":"10.1084\/JEM.20040440"},{"key":"1726_CR77","doi-asserted-by":"publisher","DOI":"10.1634\/STEMCELLS.21-1-105","author":"YA Romanov","year":"2003","unstructured":"Romanov, Y. A., Svintsitskaya, V. A. & Smirnov, V. N. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells https:\/\/doi.org\/10.1634\/STEMCELLS.21-1-105 (2003).","journal-title":"Stem Cells"},{"key":"1726_CR78","doi-asserted-by":"publisher","unstructured":"Weissenberger, M. et al. Reduced hypertrophy in vitro after chondrogenic differentiation of adult human mesenchymal stem cells following adenoviral SOX9 gene delivery. BMC Musculoskelet Disord. https:\/\/doi.org\/10.1186\/S12891-020-3137-4 (2020).","DOI":"10.1186\/S12891-020-3137-4"},{"key":"1726_CR79","doi-asserted-by":"publisher","DOI":"10.1006\/EXCR.1997.3858","author":"B Johnstone","year":"1998","unstructured":"Johnstone, B., Hering, T. M., Caplan, A. I., Goldberg, V. M. & Yoo, J. U. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp. Cell Res. https:\/\/doi.org\/10.1006\/EXCR.1997.3858 (1998).","journal-title":"Exp. Cell Res."},{"key":"1726_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2006.07.024","author":"K Takahashi","year":"2006","unstructured":"Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell https:\/\/doi.org\/10.1016\/J.CELL.2006.07.024 (2006).","journal-title":"Cell"},{"key":"1726_CR81","doi-asserted-by":"publisher","unstructured":"Zhan, J. et al. MSCs-EVs harboring OA immune memory reprogram macrophage phenotype via modulation of the mt-ND3\/NADH-CoQ axis for OA treatment. J. Nanobiotechnol. https:\/\/doi.org\/10.1186\/S12951-025-03216-1 (2025).","DOI":"10.1186\/S12951-025-03216-1"},{"key":"1726_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/STEM.2575","author":"DG Phinney","year":"2017","unstructured":"Phinney, D. G. & Pittenger, M. F. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells https:\/\/doi.org\/10.1002\/STEM.2575 (2017).","journal-title":"Stem Cells"},{"key":"1726_CR83","doi-asserted-by":"publisher","unstructured":"Hyv\u00e4rinen, K. et al. Mesenchymal stromal cells and their extracellular vesicles enhance the anti-inflammatory phenotype of regulatory macrophages by downregulating the production of interleukin (IL)-23 and IL-22. Front Immunol https:\/\/doi.org\/10.3389\/FIMMU.2018.00771 (2018).","DOI":"10.3389\/FIMMU.2018.00771"},{"key":"1726_CR84","doi-asserted-by":"publisher","unstructured":"Kang, J. et al. Adipose mesenchymal stem cells derived exosomes ameliorates KOA cartilage damage and inflammation by activation of PINK1-mediated mitochondrial autophagy. FASEB J. https:\/\/doi.org\/10.1096\/FJ.202501185R (2025).","DOI":"10.1096\/FJ.202501185R"},{"key":"1726_CR85","doi-asserted-by":"publisher","unstructured":"Xia, S., Li, L., Shi, Z., Sun, N. & He, Y. Ferroptosis in osteoarthritis: metabolic reprogramming, immunometabolic crosstalk, and targeted intervention strategies. Front. Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2025.1604652 (2025).","DOI":"10.3389\/FIMMU.2025.1604652"},{"key":"1726_CR86","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Human amniotic epithelial stem cell exosomes regulate chondrocyte ferroptosis through ACTA2-AS1 targeted binding to ACSL4 for osteoarthritis intervention. Research https:\/\/doi.org\/10.34133\/RESEARCH.0814 (2025).","DOI":"10.34133\/RESEARCH.0814"},{"key":"1726_CR87","doi-asserted-by":"publisher","unstructured":"Jiang, W. & Xu, J. Immune modulation by mesenchymal stem cells. Cell Prolif. https:\/\/doi.org\/10.1111\/CPR.12712 (2020).","DOI":"10.1111\/CPR.12712"},{"key":"1726_CR88","doi-asserted-by":"publisher","unstructured":"Larsson, S., Englund, M., Struglics, A. & Lohmander, L. S. Interleukin-6 and tumor necrosis factor alpha in synovial fluid are associated with progression of radiographic knee osteoarthritis in subjects with previous meniscectomy. Osteoarthr. Cartil. https:\/\/doi.org\/10.1016\/j.joca.2015.05.035 (2015).","DOI":"10.1016\/j.joca.2015.05.035"},{"key":"1726_CR89","doi-asserted-by":"publisher","unstructured":"Kuppa, S. S., Kim, H. K., Kang, J. Y., Lee, S. C. & Seon, J. K. Role of mesenchymal stem cells and their paracrine mediators in macrophage polarization: an approach to reduce inflammation in osteoarthritis. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/IJMS232113016 (2022).","DOI":"10.3390\/IJMS232113016"},{"key":"1726_CR90","doi-asserted-by":"publisher","unstructured":"Molnar, V. et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/IJMS22179208 (2021).","DOI":"10.3390\/IJMS22179208"},{"key":"1726_CR91","doi-asserted-by":"publisher","unstructured":"Li, S. et al. hBMSC-derived extracellular vesicles attenuate IL-1\u03b2-induced catabolic effects on OA-chondrocytes by regulating pro-inflammatory signaling pathways. Front Bioeng Biotechnol. https:\/\/doi.org\/10.3389\/FBIOE.2020.603598 (2020).","DOI":"10.3389\/FBIOE.2020.603598"},{"key":"1726_CR92","doi-asserted-by":"publisher","unstructured":"Orlowsky, E. W. & Kraus, V. B. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. J. Rheumatol. https:\/\/doi.org\/10.3899\/JRHEUM.140382 (2015).","DOI":"10.3899\/JRHEUM.140382"},{"key":"1726_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67730-y","author":"CH Chou","year":"2020","unstructured":"Chou, C. H. et al. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-020-67730-y (2020).","journal-title":"Sci. Rep."},{"key":"1726_CR94","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000892","author":"T Geraghty","year":"2021","unstructured":"Geraghty, T., Winter, D. R., Miller, R. J., Miller, R. E. & Malfait, A. M. Neuroimmune interactions and osteoarthritis pain: focus on macrophages. Pain Rep. https:\/\/doi.org\/10.1097\/PR9.0000000000000892 (2021).","journal-title":"Pain Rep."},{"key":"1726_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2011.00052","author":"A Kennedy","year":"2011","unstructured":"Kennedy, A., Fearon, U., Veale, D. J. & Godson, C. Macrophages in synovial inflammation. Front Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2011.00052 (2011).","journal-title":"Front Immunol."},{"key":"1726_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/OS.13993","author":"Z Yuan","year":"2024","unstructured":"Yuan, Z. et al. Emerging roles of macrophage polarization in osteoarthritis: mechanisms and therapeutic strategies. Orthop Surg https:\/\/doi.org\/10.1111\/OS.13993 (2024).","journal-title":"Orthop Surg"},{"key":"1726_CR97","doi-asserted-by":"publisher","unstructured":"Hamilton, A. M. et al. Iron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and suggests anti-inflammatory mechanism of action. PLoS ONE https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0214107 (2019).","DOI":"10.1371\/JOURNAL.PONE.0214107"},{"key":"1726_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2015.10.009","author":"K Mareschi","year":"2016","unstructured":"Mareschi, K. et al. Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta. Exp. Hematol https:\/\/doi.org\/10.1016\/j.exphem.2015.10.009 (2016).","journal-title":"Exp. Hematol"},{"key":"1726_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/STEM.2254","author":"P Luz-Crawford","year":"2016","unstructured":"Luz-Crawford, P. et al. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells https:\/\/doi.org\/10.1002\/STEM.2254 (2016).","journal-title":"Stem Cells"},{"key":"1726_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01358-8","author":"C Garlanda","year":"2025","unstructured":"Garlanda, C., Di Ceglie, I. & Jaillon, S. IL-1 family cytokines in inflammation and immunity. Cell Mol Immunol https:\/\/doi.org\/10.1038\/s41423-025-01358-8 (2025).","journal-title":"Cell Mol Immunol"},{"key":"1726_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2024.113954","author":"X Li","year":"2025","unstructured":"Li, X. et al. Mitochondria-rich extracellular vesicles derived from the culture supernatant of human synovial fluid-derived mesenchymal stem cells inhibited senescence of stressed\/inflammatory licensed chondrocytes and delayed osteoarthritis progression. Int Immunopharmacol https:\/\/doi.org\/10.1016\/J.INTIMP.2024.113954 (2025).","journal-title":"Int Immunopharmacol"},{"key":"1726_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-024-00375-z","author":"Z Han","year":"2024","unstructured":"Han, Z., Wang, K., Ding, S. & Zhang, M. Cross-talk of inflammation and cellular senescence: a new insight into the occurrence and progression of osteoarthritis. Bone Res https:\/\/doi.org\/10.1038\/s41413-024-00375-z (2024).","journal-title":"Bone Res"},{"key":"1726_CR103","doi-asserted-by":"publisher","unstructured":"Irwin, R. M. et al. Connexin 43 regulates intercellular mitochondrial transfer from human mesenchymal stromal cells to chondrocytes. Stem Cell Res Ther https:\/\/doi.org\/10.1186\/S13287-024-03932-9 (2024).","DOI":"10.1186\/S13287-024-03932-9"},{"key":"1726_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/J.TICE.2025.102990","author":"C Altunta\u015f","year":"2025","unstructured":"Altunta\u015f, C., Duruksu, G., Hun\u00e7, F. & Yazir, Y. Mitochondria transfer from mesenchymal stem cells into osteoarthritic chondrocytes ameliorate cellular functions and alleviate both inflammation and oxidative stress. Tissue Cell https:\/\/doi.org\/10.1016\/J.TICE.2025.102990 (2025).","journal-title":"Tissue Cell"},{"key":"1726_CR105","doi-asserted-by":"publisher","DOI":"10.1007\/S12015-021-10170-6","author":"TZ Brose","year":"2021","unstructured":"Brose, T. Z., Kubosch, E. J., Schmal, H., Stoddart, M. J. & Armiento, A. R. Crosstalk between mesenchymal stromal cells and chondrocytes: the hidden therapeutic potential for cartilage regeneration. Stem Cell Rev. Rep. https:\/\/doi.org\/10.1007\/S12015-021-10170-6 (2021).","journal-title":"Stem Cell Rev. Rep."},{"key":"1726_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS12141824\/S1","author":"D Kouroupis","year":"2023","unstructured":"Kouroupis, D., Kaplan, L. D., Huard, J. & Best, T. M. CD10-bound human mesenchymal stem\/stromal cell-derived small extracellular vesicles possess immunomodulatory cargo and maintain cartilage homeostasis under inflammatory conditions. Cells https:\/\/doi.org\/10.3390\/CELLS12141824\/S1 (2023).","journal-title":"Cells"},{"key":"1726_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS19010203","author":"T Ichiseki","year":"2018","unstructured":"Ichiseki, T. et al. Intraarticularly-injected mesenchymal stem cells stimulate anti-inflammatory molecules and inhibit pain related protein and chondrolytic enzymes in a monoiodoacetate-induced rat arthritis model. Int J Mol Sci https:\/\/doi.org\/10.3390\/IJMS19010203 (2018).","journal-title":"Int J Mol Sci"},{"key":"1726_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS12162021","author":"A Fadl","year":"2023","unstructured":"Fadl, A. & Leask, A. Hiding in plain sight: human gingival fibroblasts as an essential, yet overlooked, tool in regenerative medicine. Cells https:\/\/doi.org\/10.3390\/CELLS12162021 (2023).","journal-title":"Cells"},{"key":"1726_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-020-00109-9","author":"P Ahangar","year":"2020","unstructured":"Ahangar, P., Mills, S. J., Smith, L. E., Gronthos, S. & Cowin, A. J. Human gingival fibroblast secretome accelerates wound healing through anti-inflammatory and pro-angiogenic mechanisms. npj Regen Med. https:\/\/doi.org\/10.1038\/s41536-020-00109-9 (2020).","journal-title":"npj Regen Med."},{"key":"1726_CR110","doi-asserted-by":"publisher","DOI":"10.1177\/09636897221149445","author":"CH Chuang","year":"2023","unstructured":"Chuang, C. H. et al. Enriched peripheral blood-derived mononuclear cells for treating knee osteoarthritis. Cell Transplant https:\/\/doi.org\/10.1177\/09636897221149445 (2023).","journal-title":"Cell Transplant"},{"key":"1726_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2025.03.327","author":"V Amor-Baroukh","year":"2025","unstructured":"Amor-Baroukh, V. et al. Establishment of a robust manufacturing process for Allocetratm \u2014 a novel cell therapy platform targeting inflammatory conditions. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2025.03.327 (2025).","journal-title":"Cytotherapy"},{"key":"1726_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARD.2025.06.045","author":"E Galamidi","year":"2025","unstructured":"Galamidi, E. et al. POS0684 phase I\/II trial of Allocetratm cell therapy for knee osteoarthritis: clinical evidence of response to modulation of inflammation. Ann Rheum Dis https:\/\/doi.org\/10.1016\/J.ARD.2025.06.045 (2025).","journal-title":"Ann Rheum Dis"},{"key":"1726_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/J.RETH.2018.09.002","author":"YHK Yang","year":"2018","unstructured":"Yang, Y. H. K. Aging of mesenchymal stem cells: implication in regenerative medicine. Regen Ther https:\/\/doi.org\/10.1016\/J.RETH.2018.09.002 (2018).","journal-title":"Regen Ther"},{"key":"1726_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/S13578-021-00698-Y","author":"C Li","year":"2021","unstructured":"Li, C., Zhao, H., Cheng, L. & Wang, B. Allogeneic vs. autologous mesenchymal stem\/stromal cells in their medication practice. Cell Biosci https:\/\/doi.org\/10.1186\/S13578-021-00698-Y (2021).","journal-title":"Cell Biosci"},{"key":"1726_CR115","doi-asserted-by":"publisher","unstructured":"Cao, M. et al. Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res. Ther. https:\/\/doi.org\/10.1186\/S13287-025-04252-2 (2025).","DOI":"10.1186\/S13287-025-04252-2"},{"key":"1726_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/SCTM.17-0051","author":"AI Caplan","year":"2017","unstructured":"Caplan, A. I. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med https:\/\/doi.org\/10.1002\/SCTM.17-0051 (2017).","journal-title":"Stem Cells Transl Med"},{"key":"1726_CR117","doi-asserted-by":"publisher","unstructured":"Riggle, C., McLellan, M., Bohlen, H. & Wang, D. Complications of stem cell-based injections for knee osteoarthritis: a systematic review. HSS J https:\/\/doi.org\/10.1177\/15563316241271058 (2024).","DOI":"10.1177\/15563316241271058"},{"key":"1726_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02632-w","author":"K Mautner","year":"2023","unstructured":"Mautner, K. et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02632-w (2023).","journal-title":"Nat. Med."},{"key":"1726_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53598-9","author":"SH Jung","year":"2024","unstructured":"Jung, S. H. et al. Allogeneic umbilical cord blood-derived mesenchymal stem cell implantation versus microdrilling combined with high tibial osteotomy for cartilage regeneration. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-024-53598-9 (2024).","journal-title":"Sci. Rep."},{"key":"1726_CR120","doi-asserted-by":"publisher","unstructured":"Bae, B. S. et al. Treatment of osteoarthritic knee with high tibial osteotomy and allogeneic human umbilical cord blood-derived mesenchymal stem cells combined with hyaluronate hydrogel composite. Stem Cell Res. Ther. https:\/\/doi.org\/10.1186\/S13287-025-04356-9 (2025).","DOI":"10.1186\/S13287-025-04356-9"},{"key":"1726_CR121","doi-asserted-by":"publisher","unstructured":"Lim, H. C. et al. Allogeneic umbilical cord blood-derived mesenchymal stem cell implantation versus microfracture for large, full-thickness cartilage defects in older patients: a multicenter randomized clinical trial and extended 5-year clinical follow-up. Orthop J Sports Med. https:\/\/doi.org\/10.1177\/2325967120973052 (2021).","DOI":"10.1177\/2325967120973052"},{"key":"1726_CR122","doi-asserted-by":"publisher","DOI":"10.5966\/SCTM.2016-0157","author":"YB Park","year":"2017","unstructured":"Park, Y. B. et al. Cartilage regeneration in osteoarthritic patients by a composite of allogeneic umbilical cord blood-derived mesenchymal stem cells and hyaluronate hydrogel: results from a clinical trial for safety and proof-of-concept with 7 years of extended follow-up. Stem Cells Transl Med https:\/\/doi.org\/10.5966\/SCTM.2016-0157 (2017).","journal-title":"Stem Cells Transl Med"},{"key":"1726_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/KSA.12100","author":"SH Jung","year":"2024","unstructured":"Jung, S. H. et al. Implantation of hUCB-MSCs generates greater hyaline-type cartilage than microdrilling combined with high tibial osteotomy. Knee Surg Sports Traumatol Arthrosc https:\/\/doi.org\/10.1002\/KSA.12100 (2024).","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"1726_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARTHRO.2021.02.022","author":"NH Lee","year":"2021","unstructured":"Lee, N. H. et al. Allogenic human umbilical cord blood-derived mesenchymal stem cells are more effective than bone marrow aspiration concentrate for cartilage regeneration after high tibial osteotomy in medial unicompartmental osteoarthritis of knee. Arthroscopy https:\/\/doi.org\/10.1016\/J.ARTHRO.2021.02.022 (2021).","journal-title":"Arthroscopy"},{"key":"1726_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA59010148","author":"B Lee","year":"2023","unstructured":"Lee, B. et al. Allogeneic umbilical cord-blood-derived mesenchymal stem cells and hyaluronate composite combined with high tibial osteotomy for medial knee osteoarthritis with full-thickness cartilage defects. Medicina https:\/\/doi.org\/10.3390\/MEDICINA59010148 (2023).","journal-title":"Medicina"},{"key":"1726_CR126","doi-asserted-by":"publisher","DOI":"10.1007\/S00167-021-06450-W","author":"HY Yang","year":"2022","unstructured":"Yang, H. Y. et al. Allogenic umbilical cord blood-derived mesenchymal stromal cell implantation was superior to bone marrow aspirate concentrate augmentation for cartilage regeneration despite similar clinical outcomes. Knee Surg Sports Traumatol Arthrosc https:\/\/doi.org\/10.1007\/S00167-021-06450-W (2022).","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"1726_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2025.02.301","author":"PK Gupta","year":"2025","unstructured":"Gupta, P. K. et al. Allogeneic, off the shelf, pooled, bone marrow derived mesenchymal stromal cells (STEMPEUCEL\u00ae) \u2014 results: from pivotal trials of a commercially approved therapy in India for grade II & III osteoarthritis knee.Osteoarthr Cartil https:\/\/doi.org\/10.1016\/j.joca.2025.02.301 (2025).","journal-title":"Osteoarthr Cartil"},{"key":"1726_CR128","doi-asserted-by":"publisher","DOI":"10.1177\/03635465231180323","author":"PK Gupta","year":"2023","unstructured":"Gupta, P. K. et al. Efficacy and safety of Stempeucel in osteoarthritis of the knee: a phase 3 randomized, double-blind, multicenter, placebo-controlled study. Am J Sports Med https:\/\/doi.org\/10.1177\/03635465231180323 (2023).","journal-title":"Am J Sports Med"},{"key":"1726_CR129","doi-asserted-by":"publisher","unstructured":"Gupta, P. K. et al. Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel\u00ae): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther https:\/\/doi.org\/10.1186\/S13075-016-1195-7 (2016).","DOI":"10.1186\/S13075-016-1195-7"},{"key":"1726_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCOT.2022.101804","author":"V Pandey","year":"2022","unstructured":"Pandey, V., Madi, S. & Gupta, P. The promising role of autologous and allogeneic mesenchymal stromal cells in managing knee osteoarthritis. What is beyond mesenchymal stromal cells? J Clin Orthop Trauma https:\/\/doi.org\/10.1016\/J.JCOT.2022.101804 (2022).","journal-title":"J Clin Orthop Trauma"},{"key":"1726_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/JCB.24193","author":"MK Mamidi","year":"2012","unstructured":"Mamidi, M. K. et al. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. J Cell Biochem https:\/\/doi.org\/10.1002\/JCB.24193 (2012).","journal-title":"J Cell Biochem"},{"key":"1726_CR132","doi-asserted-by":"publisher","unstructured":"Kuah, D. et al. Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study. J Transl. Med. https:\/\/doi.org\/10.1186\/S12967-018-1420-Z (2018).","DOI":"10.1186\/S12967-018-1420-Z"},{"key":"1726_CR133","doi-asserted-by":"publisher","unstructured":"Lee, H. et al. TissueGene-C promotes an anti-inflammatory micro-environment in a rat monoiodoacetate model of osteoarthritis via polarization of M2 macrophages leading to pain relief and structural improvement. Inflammopharmacology https:\/\/doi.org\/10.1007\/S10787-020-00738-Y (2020).","DOI":"10.1007\/S10787-020-00738-Y"},{"key":"1726_CR134","doi-asserted-by":"publisher","unstructured":"Yoon, H. J. et al. Type II collagen and glycosaminoglycan expression induction in primary human chondrocyte by TGF-\u03b21. BMC Musculoskelet Disord https:\/\/doi.org\/10.1186\/S12891-015-0599-X (2015).","DOI":"10.1186\/S12891-015-0599-X"},{"key":"1726_CR135","doi-asserted-by":"publisher","unstructured":"Ankri, C. et al. Safety of repeated administration of xenogeneic human apoptotic state (Allocetra-OTS) in Sprague Dawley rats. Pharmaceutics https:\/\/doi.org\/10.3390\/PHARMACEUTICS16030426 (2024).","DOI":"10.3390\/PHARMACEUTICS16030426"},{"key":"1726_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2025.03.328","author":"C Ankri","year":"2025","unstructured":"Ankri, C. et al. Pre-clinical characterization of Allocetratm: a novel macrophage reprogramming cell therapy, for intra-articular treatment in osteoarthritis. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2025.03.328 (2025).","journal-title":"Cytotherapy"},{"key":"1726_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2024.02.073","author":"T Maleitzke","year":"2024","unstructured":"Maleitzke, T. et al. A single placenta-derived mesenchymal-like stromal cell injection halts progression of primary knee osteoarthritis \u2014 first preclinical results from the PROTO consortium. Osteoarthr Cartil https:\/\/doi.org\/10.1016\/j.joca.2024.02.073 (2024).","journal-title":"Osteoarthr Cartil"},{"key":"1726_CR138","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.8.1241","author":"WR Prather","year":"2008","unstructured":"Prather, W. R., Toren, A. & Meiron, M. Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood. Exp. Opin Biol. Ther https:\/\/doi.org\/10.1517\/14712598.8.8.1241 (2008).","journal-title":"Exp. Opin Biol. Ther"},{"key":"1726_CR139","doi-asserted-by":"publisher","unstructured":"Ying, W. et al. Cell and gene therapy approvals in Asia: regulatory landscape, access, and affordability. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2025.08.005 (2025).","DOI":"10.1016\/J.JCYT.2025.08.005"},{"key":"1726_CR140","doi-asserted-by":"publisher","DOI":"10.1111\/OS.12088","author":"HR Bin Abd Razak","year":"2014","unstructured":"Bin Abd Razak, H. R., Han, X. A., Chong, H. C. & Tan, H. C. A. Total knee arthroplasty in Asian subjects: preoperative range of motion determines postoperative range of motion? Orthop Surg https:\/\/doi.org\/10.1111\/OS.12088 (2014).","journal-title":"Orthop Surg"},{"key":"1726_CR141","doi-asserted-by":"publisher","unstructured":"Budhiparama, N. C. et al. A comparison of clinical and patient-reported outcome measures of TKR: comparison of Asian to North American patients. J Orthopaed Surg https:\/\/doi.org\/10.1177\/2309499019844551 (2019).","DOI":"10.1177\/2309499019844551"},{"key":"1726_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02269-w","author":"I Zugasti","year":"2025","unstructured":"Zugasti, I. et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther https:\/\/doi.org\/10.1038\/s41392-025-02269-w (2025).","journal-title":"Signal Transduct Target Ther"},{"key":"1726_CR143","unstructured":"NCD - Chimeric Antigen Receptor (CAR) T-cell Therapy (110.24) [Internet]. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncd.aspx?ncdid=374 (2026)."},{"key":"1726_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/SCRT217","author":"L Senseb\u00e9","year":"2013","unstructured":"Senseb\u00e9, L., Gadelorge, M. & Fleury-Cappellesso, S. Production of mesenchymal stromal\/stem cells according to good manufacturing practices: a review. Stem Cell Res Ther https:\/\/doi.org\/10.1186\/SCRT217 (2013).","journal-title":"Stem Cell Res Ther"},{"key":"1726_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.05.004","author":"J Galipeau","year":"2018","unstructured":"Galipeau, J. & Sens\u00e9b\u00e9, L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell https:\/\/doi.org\/10.1016\/j.stem.2018.05.004 (2018).","journal-title":"Cell Stem Cell"},{"key":"1726_CR146","doi-asserted-by":"publisher","unstructured":"Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. https:\/\/doi.org\/10.1126\/SCIADV.ABA6884 (2020).","DOI":"10.1126\/SCIADV.ABA6884"},{"key":"1726_CR147","doi-asserted-by":"publisher","unstructured":"Hanna, E., R\u00e9muzat C., Auquier P., Toumi M. Advanced therapy medicinal products: current and future perspectives. J Mark Access Health Policy https:\/\/doi.org\/10.3402\/JMAHP.V4.31036 (2016).","DOI":"10.3402\/JMAHP.V4.31036"},{"key":"1726_CR148","doi-asserted-by":"publisher","DOI":"10.2217\/RME.14.73","author":"TR Heathman","year":"2015","unstructured":"Heathman, T. R. et al. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med https:\/\/doi.org\/10.2217\/RME.14.73 (2015).","journal-title":"Regen Med"},{"key":"1726_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/J.STEM.2016.08.012","author":"M Abou-El-Enein","year":"2016","unstructured":"Abou-El-Enein, M., Elsanhoury, A. & Reinke, P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell https:\/\/doi.org\/10.1016\/J.STEM.2016.08.012 (2016).","journal-title":"Cell Stem Cell"},{"key":"1726_CR150","doi-asserted-by":"publisher","DOI":"10.15252\/EMMM.201607485","author":"J Hartmann","year":"2017","unstructured":"Hartmann, J., Sch\u00fc\u00dfler-Lenz, M., Bondanza, A. & Buchholz, C. J. Clinical development of CAR T cells \u2014 challenges and opportunities in translating innovative treatment concepts. EMBO Mol. Med. https:\/\/doi.org\/10.15252\/EMMM.201607485 (2017).","journal-title":"EMBO Mol. Med."},{"key":"1726_CR151","unstructured":"FDA. FDA approves first mesenchymal stromal cell therapy to treat steroid-refractory acute graft-versus-host disease [Internet]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host (2025)."},{"key":"1726_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBMT.2020.01.018","author":"J Kurtzberg","year":"2020","unstructured":"Kurtzberg, J. et al. A phase 3, single-arm, prospective study of Remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant https:\/\/doi.org\/10.1016\/J.BBMT.2020.01.018 (2020).","journal-title":"Biol Blood Marrow Transplant"},{"key":"1726_CR153","unstructured":"FDA. Osteoarthritis: structural endpoints for the development of drugs. [Internet] (2025) https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/osteoarthritis-structural-endpoints-development-drugs."},{"key":"1726_CR154","unstructured":"FDA. Approaches to assessment of overall survival in oncology clinical trials. [Internet] (2025) https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/approaches-assessment-overall-survival-oncology-clinical-trials."},{"key":"1726_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.01.013","author":"M Mendicino","year":"2014","unstructured":"Mendicino, M., Bailey, A. M., Wonnacott, K., Puri, R. K. & Bauer, S. R. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell https:\/\/doi.org\/10.1016\/j.stem.2014.01.013 (2014).","journal-title":"Cell Stem Cell"},{"key":"1726_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2012.10.008","author":"CA Bravery","year":"2013","unstructured":"Bravery, C. A. et al. Potency assay development for cellular therapy products: an ISCT* review of the requirements and experiences in the industry. Cytotherapy https:\/\/doi.org\/10.1016\/j.jcyt.2012.10.008 (2013).","journal-title":"Cytotherapy"},{"key":"1726_CR157","unstructured":"FDA. Safety testing of human allogeneic cells expanded for use in cell-based medical products. [Internet]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-testing-human-allogeneic-cells-expanded-use-cell-based-medical-products (2025)."},{"key":"1726_CR158","unstructured":"FDA. Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs).\u2009[Internet]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/content-and-review-chemistry-manufacturing-and-control-cmc-information-human-somatic-cell-therapy (2025)."},{"key":"1726_CR159","unstructured":"FDA. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)\u2009[Internet]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug (2025)."},{"key":"1726_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.07.006","author":"YH Koog","year":"2013","unstructured":"Koog, Y. H., Gil, M., We, S. R., Wi, H. & Min, B. Barriers to participant retention in knee osteoarthritis clinical trials: a systematic review. Semin Arthritis Rheum https:\/\/doi.org\/10.1016\/j.semarthrit.2012.07.006 (2013).","journal-title":"Semin Arthritis Rheum"},{"key":"1726_CR161","doi-asserted-by":"publisher","unstructured":"Patten, R. K. et al. Digital self-management interventions for osteoarthritis: a systematic scoping review of intervention characteristics, adherence and attrition. Arch Public Health https:\/\/doi.org\/10.1186\/S13690-022-00854-X (2022).","DOI":"10.1186\/S13690-022-00854-X"},{"key":"1726_CR162","doi-asserted-by":"publisher","unstructured":"Koog, Y. H., Lee, J. S. & Wi, H. Nonspecific adverse events in knee osteoarthritis clinical trials: a systematic review. PLoS ONE https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0111776 (2014).","DOI":"10.1371\/JOURNAL.PONE.0111776"},{"key":"1726_CR163","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5859729","author":"H Cramer","year":"2016","unstructured":"Cramer, H., Haller, H., Dobos, G. & Lauche, R. A systematic review and meta-analysis estimating the expected dropout rates in randomized controlled trials on yoga interventions. Evid Based Complement Alternat Med https:\/\/doi.org\/10.1155\/2016\/5859729 (2016).","journal-title":"Evid Based Complement Alternat Med"},{"key":"1726_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2018.05.019","author":"J Scott","year":"2018","unstructured":"Scott, J. et al. An observational analysis of discontinuation and non-publication of osteoarthritis trials. Osteoarthr Cartil https:\/\/doi.org\/10.1016\/j.joca.2018.05.019 (2018).","journal-title":"Osteoarthr Cartil"},{"key":"1726_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60690-X","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(08)60690-X (2008).","journal-title":"Lancet"},{"key":"1726_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.52","author":"RJ Powell","year":"2012","unstructured":"Powell, R. J. et al. Cellular therapy with ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Therhttps:\/\/doi.org\/10.1038\/mt.2012.52 (2012).","journal-title":"Mol Ther"},{"key":"1726_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31203-X","author":"J Pan\u00e9s","year":"2016","unstructured":"Pan\u00e9s, J. et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(16)31203-X (2016).","journal-title":"Lancet"},{"key":"1726_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2025.102016","author":"T Tertel","year":"2025","unstructured":"Tertel, T. et al. ISCT 2025 exosomes signature series: a thematic synthesis for advancing MSC EV therapies. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2025.102016 (2025).","journal-title":"Cytotherapy"},{"key":"1726_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2025.03.505","author":"B Giebel","year":"2025","unstructured":"Giebel, B. & Lim, S. K. Overcoming challenges in MSC-sEV therapeutics: insights and advances after a decade of research. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2025.03.505(2025).","journal-title":"Cytotherapy"},{"key":"1726_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/J.RETH.2025.02.008","author":"S Terai","year":"2025","unstructured":"Terai, S. et al. Guidance on the clinical application of extracellular vesicles. Regen Ther https:\/\/doi.org\/10.1016\/J.RETH.2025.02.008 (2025).","journal-title":"Regen Ther"},{"key":"1726_CR171","unstructured":"Physician Fee Schedule | CMS [Internet]. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/physician (2025)."},{"key":"1726_CR172","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1055\/s-0038-1669953","volume":"32","author":"NS Piuzzi","year":"2019","unstructured":"Piuzzi, N. S. et al. What is the price and claimed efficacy of platelet-rich plasma injections for the treatment of knee osteoarthritis in the United States? J Knee Surg 32, 879\u2013885. https:\/\/doi.org\/10.1055\/s-0038-1669953 (2019).","journal-title":"J Knee Surg"},{"key":"1726_CR173","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.F.00222","author":"S Kurtz","year":"2007","unstructured":"Kurtz, S., Ong, K., Lau, E., Mowat, F. & Halpern, M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am https:\/\/doi.org\/10.2106\/JBJS.F.00222 (2007).","journal-title":"J Bone Joint Surg Am"},{"key":"1726_CR174","doi-asserted-by":"publisher","unstructured":"Gandhi, N. et al. Costs and models used in the economic analysis of total knee replacement (TKR): a systematic review. PLoS ONE https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0280371 (2023).","DOI":"10.1371\/JOURNAL.PONE.0280371"},{"key":"1726_CR175","unstructured":"Overview | Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | Guidance | NICE [Internet]. https:\/\/www.nice.org.uk\/guidance\/ta477 (2025)."},{"key":"1726_CR176","unstructured":"MACI (autologous cultured chondrocytes on porcine collagen membrane) | FDA [Internet]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane (2025)."},{"key":"1726_CR177","doi-asserted-by":"publisher","DOI":"10.1186\/S40634-014-0010-0","author":"E Kon","year":"2014","unstructured":"Kon, E., Filardo, G., Perdisa, F., Venieri, G. & Marcacci, M. Clinical results of multilayered biomaterials for osteochondral regeneration. J Exp Orthop https:\/\/doi.org\/10.1186\/S40634-014-0010-0 (2014).","journal-title":"J Exp Orthop"},{"key":"1726_CR178","doi-asserted-by":"publisher","DOI":"10.2217\/17460751.4.1.1","author":"C Mason","year":"2009","unstructured":"Mason, C. & Manzotti, E. New era dawns for US stem cell research. Regen Med https:\/\/doi.org\/10.2217\/17460751.4.1.1 (2009).","journal-title":"Regen Med"},{"key":"1726_CR179","doi-asserted-by":"publisher","unstructured":"Peitso, V. et al. Gene therapy pipelines for osteoarthritis: current innovations, operational challenges, and future directions. Connect Tissue Res https:\/\/doi.org\/10.1080\/03008207.2025.2520319 (2025).","DOI":"10.1080\/03008207.2025.2520319"},{"key":"1726_CR180","doi-asserted-by":"publisher","DOI":"10.1007\/S40259-025-00728-Y","author":"Q Pang","year":"2025","unstructured":"Pang, Q., Zhan, J., Chen, Z., Dong, L. & Huang, W. Emerging therapy in osteoarthritis: mesenchymal stem cells, secretomes, and using hydrogels to enhance efficacy. BioDrugs https:\/\/doi.org\/10.1007\/S40259-025-00728-Y (2025).","journal-title":"BioDrugs"},{"key":"1726_CR181","doi-asserted-by":"publisher","DOI":"10.7150\/THNO.21072","author":"S Cosenza","year":"2018","unstructured":"Cosenza, S. et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics https:\/\/doi.org\/10.7150\/THNO.21072 (2018).","journal-title":"Theranostics"},{"key":"1726_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.06.003","author":"B Olalla","year":"2024","unstructured":"Olalla, B. & R\u00edo, P. A new breakthrough in genome editing: the story of Casgevy. Cytotherapy https:\/\/doi.org\/10.1016\/j.jcyt.2024.06.003 (2024).","journal-title":"Cytotherapy"},{"key":"1726_CR183","unstructured":"CASGEVY\u2009|\u2009FDA [Internet]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/casgevy (2025)."},{"key":"1726_CR184","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.1225829","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science https:\/\/doi.org\/10.1126\/SCIENCE.1225829 (2012).","journal-title":"Science"},{"key":"1726_CR185","doi-asserted-by":"publisher","unstructured":"Ali, E. A. M. et al. iPSCs chondrogenic differentiation for personalized regenerative medicine: a literature review. Stem Cell Res. Ther. https:\/\/doi.org\/10.1186\/S13287-024-03794-1 (2024).","DOI":"10.1186\/S13287-024-03794-1"},{"key":"1726_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2023.06.003","author":"H Vignes","year":"2023","unstructured":"Vignes, H., Smaida, R., Conzatti, G., Hua, G. & Benkirane-Jessel, N. Custom-made meniscus biofabrication. Trends Biotechnol https:\/\/doi.org\/10.1016\/j.tibtech.2023.06.003 (2023).","journal-title":"Trends Biotechnol"},{"key":"1726_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2024.12.002","author":"BL Walton","year":"2025","unstructured":"Walton, B. L. et al. A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine. Osteoarthr Cartil https:\/\/doi.org\/10.1016\/j.joca.2024.12.002 (2025).","journal-title":"Osteoarthr Cartil"},{"key":"1726_CR188","doi-asserted-by":"publisher","unstructured":"Martinez-Zalbidea, I. et al. CRISPR-dCas9 activation of TSG-6 in MSCs modulates the cargo of MSC-derived extracellular vesicles and attenuates inflammatory responses in human intervertebral disc cells in vitro. Cell Mol. Bioeng https:\/\/doi.org\/10.1007\/S12195-025-00843-4 (2025).","DOI":"10.1007\/S12195-025-00843-4"},{"key":"1726_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCYT.2013.02.010","author":"M Krampera","year":"2013","unstructured":"Krampera, M., Galipeau, J., Shi, Y., Tarte, K. & Sensebe, L. Immunological characterization of multipotent mesenchymal stromal cells \u2014 The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy https:\/\/doi.org\/10.1016\/J.JCYT.2013.02.010 (2013).","journal-title":"Cytotherapy"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01726-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:06:52Z","timestamp":1782914812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01726-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":189,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01726-y","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.W. currently consults for the following companies: Heraeus Medical, Pluri, Enlivex, Liposphere, Causeway Therapeutics, and ReLive. J.-Y.R. is President of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and Co-Founder and Board member of the International Osteoporosis Foundation. A.M. currently consults for the following cell therapy companies: Kangstem, Pluri, Enlivex, and Kolon TissueGene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, Microsoft Copilot was partially used by V.P. to refine the text. All content generated with this tool was reviewed and edited by V.P., who takes full responsibility for the final version of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies"}}]}}